{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"75","upperLimit":"100","value":"88"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Distribution will be estimated using standard survival analysis techniques, and the K-M method. From the K-M life tables, both point and 90% CI estimates of various statistics of interest can be calculated (e.g., median, 6-month event-free rate, 12-month event-free rate, etc.). Statistical graphs of each K-M curve (with 90% CI lines) will be generated for visual display.\n\n(One year survival rate will be given since OS median was not reached due to too few events)","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nVorinostat: Given PO","id":"OG000","title":"Treatment (Vorinostat)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From the start of treatment until death from any cause, duration for reported probability= 1 year; survival data collected for up to a total of 60 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"percentage of participants surviving 1yr"}